SCHEMBL7658693

SCHEMBL7658693

CCc1cc2c(s1)Oc1ccccc1NC2=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
MAPT P10636 7/20 0.44
MEN1 O00255 6/20 0.44
KMT2A Q03164 6/20 0.44
POLB P06746 5/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
ALDH1A1 P00352 1/20 0.44
EGFR P00533 1/20 0.43
TP53 P04637 2/20 0.43
ALOX5 P09917 2/20 0.40
ACVR1 Q04771 2/20 0.37
LRRK2 Q5S007 2/20 0.37
ROS1 P08922 1/20 0.37
CDK5 Q00535 1/20 0.37
PDGFRA P16234 1/20 0.37
FER P16591 1/20 0.37
LTK P29376 1/20 0.37
CDK8 P49336 1/20 0.37
DYRK1B Q9Y463 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7660124 0.89 LMNA (0.43) LMNAMAPTMEN1KMT2APOLB
SCHEMBL7666437 0.87 LMNA (0.41) LMNAMAPTMEN1KMT2APOLB
SCHEMBL7661703 0.86 LMNA (0.44) LMNAMAPTMEN1KMT2APOLB
SCHEMBL7666535 0.85 LMNA (0.42) LMNAMAPTMEN1KMT2APOLB
SCHEMBL7658523 0.83 MAPT (0.47) LMNAMAPTMEN1KMT2APOLB
SCHEMBL7653416 0.81 MAPT (0.40) LMNAMAPTMEN1KMT2APOLB
SCHEMBL7653766 0.80 MAPT (0.46) LMNAMAPTMEN1KMT2APOLB
SCHEMBL7661726 0.80 MAPT (0.43) LMNAMAPTMEN1KMT2APOLB
Dimethylamine SCHEMBL7666545 0.80 MAPT (0.44) LMNAMAPTMEN1KMT2APOLB
SCHEMBL7656028 0.79 MAPT (0.39) LMNAMAPTMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US claimed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP claimed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT LMNA 4763/4885MAPT 15/4885MEN1 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.